TNGX FY2025 EPS Forecast Lifted by Cantor Fitzgerald

Key Points

• Cantor Fitzgerald has upgraded their FY2025 earnings per share estimate for Tango Therapeutics from ($1.35) to ($0.97), reflecting improved expectations for the company's financial performance.
• Guggenheim and HC Wainwright have both issued "buy" ratings for Tango Therapeutics, with price targets of $10.00 and $13.00 respectively, suggesting strong market confidence in the company's future growth.
• As of the latest quarter, Tango Therapeutics reported earnings of ($0.35) per share, meeting analysts' expectations but falling short on revenue with $3.18 million compared to the forecasted $6.41 million.

Tango Therapeutics, Inc. (NASDAQ:TNGX - Free Report) - Equities researchers at Cantor Fitzgerald increased their FY2025 earnings estimates for Tango Therapeutics in a research report issued to clients and investors on Wednesday, August 6th. Cantor Fitzgerald analyst E. Schmidt now forecasts that the company will post earnings of ($0.97) per share for the year, up from their prior forecast of ($1.35). The consensus estimate for Tango Therapeutics' current full-year earnings is ($1.19) per share. Cantor Fitzgerald also issued estimates for Tango Therapeutics' FY2026 earnings at ($1.83) EPS.

Other equities analysts have also recently issued research reports about the stock. HC Wainwright reiterated a "buy" rating and issued a $13.00 price objective on shares of Tango Therapeutics in a research note on Monday, April 14th. Guggenheim lifted their price target on shares of Tango Therapeutics from $8.00 to $10.00 and gave the stock a "buy" rating in a research note on Wednesday, August 6th.

Tango Therapeutics Trading Up 5.4%

TNGX stock traded up $0.34 during trading on Friday, reaching $6.75. The stock had a trading volume of 572,118 shares, compared to its average volume of 1,768,063. The stock's 50 day moving average is $5.63 and its two-hundred day moving average is $3.20. The firm has a market cap of $751.45 million, a PE ratio of -5.03 and a beta of 1.64. Tango Therapeutics has a 52 week low of $1.03 and a 52 week high of $12.02.

Tango Therapeutics (NASDAQ:TNGX - Get Free Report) last announced its earnings results on Tuesday, August 5th. The company reported ($0.35) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.35). The business had revenue of $3.18 million during the quarter, compared to analyst estimates of $6.41 million. Tango Therapeutics had a negative net margin of 599.11% and a negative return on equity of 79.72%.

Institutional Investors Weigh In On Tango Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Deutsche Bank AG raised its position in shares of Tango Therapeutics by 24.1% during the 4th quarter. Deutsche Bank AG now owns 36,653 shares of the company's stock valued at $113,000 after purchasing an additional 7,128 shares during the period. Ameriprise Financial Inc. purchased a new position in shares of Tango Therapeutics in the fourth quarter valued at about $35,000. Squarepoint Ops LLC bought a new position in shares of Tango Therapeutics in the fourth quarter worth about $40,000. Northern Trust Corp boosted its stake in shares of Tango Therapeutics by 7.1% in the fourth quarter. Northern Trust Corp now owns 513,079 shares of the company's stock worth $1,585,000 after acquiring an additional 33,829 shares during the period. Finally, Millennium Management LLC purchased a new stake in shares of Tango Therapeutics during the fourth quarter worth about $771,000. Institutional investors own 78.99% of the company's stock.

Tango Therapeutics Company Profile

Tango Therapeutics, Inc, a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions.